Identification of host-immune response protein candidates in the sera of human oral squamous cell carcinoma patients

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Chen, Yeng ^a   Azman, Siti Nuraishah ^b   Kerishnan, Jesinda P ^a   Zain, Rosnah Binti ^a   Chen, Yu Nieng ^c   Wong, Yin Ling ^a   Gopinath, Subash C B ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^c Chen Dental Specialist Clinic Kueh Hock Kui Commercial Centre Jalan Tun Ahmad Zaidi Adruce   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 GLYCOPROTEIN; ALPHA2 GLYCOPROTEIN; BACTERIAL ANTIGEN; CLUSTERIN; COMPLEMENT COMPONENT C3C; HAPTOGLOBIN; ONCOPROTEIN; PROAPOLIPOPROTEIN A1; PROTEIN PRECURSOR; PROTEIN PRO2044; RETINOL BINDING PROTEIN 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ACINETOBACTER LWOFFII; AMINO ACID SEQUENCE; ARTICLE; BURKHOLDERIA MULTIVORANS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EARLY DIAGNOSIS; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOREACTIVITY; LARIBACTER HONGKONGENSIS; MASS SPECTROMETRY; MOUTH SQUAMOUS CELL CARCINOMA; MYXOCOCCUS XANTHUS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DATABASE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SILVER STAINING; STREPTOCOCCUS SALIVARIUS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; BLOOD; IMMUNOLOGY; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; HUMANS; MOUTH NEOPLASMS;

EID: 84907569397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109012     Document Type: Article

References (88)

1. Parkin DM, Bray F, Ferlay J., Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Arellano-Garcia ME, Li R, Liu X., Xie Y, Yan X, et al. (2010) Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci 11: 3106-3121.
3. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
4. Neville BW, Day T.A. (2002) Oral cancer and precancerous lesions. CA Cancer J Clin 52: 195-215.
5. Forastiere AA, Goepfert H, Maor M., Pajak TF, Weber R, et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098.
6. Lin HS, Talwar HS, Tarca A.L., Ionan A., Chatterjee M, et al. (2007) Autoantibody approach for serum-based detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 16: 2396-2405.
7. da Silva SD, Ferlito A, Takes R.P., Brakenhoff RH, Valentin MD, et al. (2011) Advances and applications of oral cancer basic research. Oral Oncol 47: 783-791.
8. Whitmore SE, Lamont R.J. (2014) Oral bacteria and cancer. PLoS Pathog 10: e1003933.
9. Lingen MW, Kalmar JR, Karrison T, Speight P.M. (2008) Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 44: 10-22.
10. Day GL, Blot W.J. (1992) Second primary tumors in patients with oral cancer. Cancer 70: 14-19.
11. Mou Z, He Y, Wu Y. (2009) Immunoproteomics to identify tumor-associated antigens eliciting humoral response. Cancer Lett 278: 123-129.
12. Arnott D, Emmert-Buck MR (2010) Proteomic profiling of cancer-opportunities, challenges, and context. J Pathol 222: 16-20.
13. Goldszmid RS, Dzutsev A, Trinchieri G. (2014) Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe 15: 295-305.
14. Chen Y, Lim BK, Peh S.C., Abdul-Rahman PS, Hashim O.H. (2008) Profiling of serum and tissue high abundance acute-phase proteins of patients with epithelial and germ line ovarian carcinoma. Proteome Sci 6: 20.
15. Heukeshoven J, Dernick R. (1988) Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 9: 28-32.
16. Shevchenko A, Wilm M, Vorm O., Mann M. (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
17. Huang da W, Sherman BT, Lempicki R.A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
18. Franceschini A, Szklarczyk D, Frankild S., Kuhn M, Simonovic M, et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808-815.
19. Bini L, Magi B, Marzocchi B., Cellesi C, Berti B, et al. (1996) Two-dimensional electrophoretic patterns of acute-phase human serum proteins in the course of bacterial and viral diseases. Electrophoresis 17: 612-616.
20. Chen JH, Chang YW, Yao C.W., Chiueh TS, Huang SC, et al. (2004) Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc Natl Acad Sci U S A 101: 17039-17044.
21. Kakisaka T, Kondo T, Okano T., Fujii K, Honda K, et al. (2007) Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chroma-tography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chroma-togr B Analyt Technol Biomed Life Sci 852: 257-267.
22. Kawakami T, Hoshida Y, Kanai F., Tanaka Y, Tateishi K, et al. (2005) Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 5: 4287-4295.
23. Okano T, Kondo T, Kakisaka T., Fujii K, Yamada M, et al. (2006) Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatog-raphy and two-dimensional difference gel electrophoresis. Proteomics 6: 3938-3948.
24. Weivoda S, Andersen JD, Skogen A, Schlievert P.M., Fontana D., et al. (2008) ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J Immunol Methods 336: 22-29.
25. Li C, Zolotarevsky E, Thompson I., Anderson MA, Simeone DM, et al. (2011) A multiplexed bead assay for profiling glycosylation patterns on serum protein biomarkers of pancreatic cancer. Electrophoresis 32: 2028-2035.
26. Kreunin P, Zhao J, Rosser C., Urquidi V, Lubman DM, et al. (2007) Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 6: 2631-2639.
27. Liu Y, Luo X, Hu H., Wang R, Sun Y, et al. (2012) Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLoS One 7: e51748.
28. Jeong DH, Kim HK, Prince A.E., Lee DS, Kim YN, et al. (2008) Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol 19: 173-180.
29. Stejskal D, Fiala R.R. (2006) Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma 53: 343-346.
30. Redondo M, Villar E, Torres-Munoz J, Tellez T., Morell M, et al. (2000) Overexpression of clusterin in human breast carcinoma. Am J Pathol 157: 393-399.
31. Rodriguez-Pineiro AM, de la Cadena MP, Lopez-Saco A, Rodriguez-Berrocal FJ (2006) Differential expression of serum clusterin isoforms in colorectal cancer. Mol Cell Proteomics 5: 1647-1657.
32. Xie MJ, Motoo Y, Su S.B., Mouri H., Ohtsubo K, et al. (2002) Expression of clusterin in human pancreatic cancer. Pancreas 25: 234-238.
33. Zellweger T, Chi K, Miyake H., Adomat H, Kiyama S, et al. (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8: 3276-3284.
34. Scaltriti M, Brausi M, Amorosi A., Caporali A, D'Arca D, et al. (2004) Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 108: 23-30.
35. Zhang LY, Ying WT, Mao Y.S., He HZ, Liu Y, et al. (2003) Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 9: 650-654.
36. Santilli G, Aronow BJ, Sala A. (2003) Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem 278: 38214-38219.
37. Wei L, Xue T, Wang J., Chen B, Lei Y, et al. (2009) Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer 125: 791-806.
38. Wu J, Xie X, Nie S., Buckanovich RJ, Lubman D.M. (2013) Altered expression of sialylated glycoproteins in ovarian cancer sera using lectin-based ELISA assay and quantitative glycoproteomics analysis. J Proteome Res 12: 3342-3352.
39. Lourda M, Trougakos IP, Gonos E.S. (2007) Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int J Cancer 120: 611-622.
40. Redondo M, Rodrigo I, Alcaide J., Tellez T, Roldan MJ, et al. (2010) Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas. Histopathology 56: 932-936.
41. Trougakos IP, Lourda M, Agiostratidou G., Kletsas D, Gonos E.S. (2005) Differential effects of clusterin/apolipoprotein J on cellular growth and survival. Free Radic Biol Med 38: 436-449.
42. Jin T, Hu LS, Chang M, Wu J., Winblad B, et al. (2007) Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol 14: 563-568.
43. Kuhajda FP, Katumuluwa AI, Pasternack G.R. (1989) Expression of haptoglobin-related protein and its potential role as a tumor antigen. Proc Natl Acad Sci U S A 86: 1188-1192.
44. Ahmed N, Barker G, Oliva K.T., Hoffmann P., Riley C, et al. (2004) Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 91: 129-140.
45. Lai CH, Chang NW, Lin C.F., Lin CD, Lin YJ, et al. (2010) Proteomics-based identification of haptoglobin as a novel plasma biomarker in oral squamous cell carcinoma. Clin Chim Acta 411: 984-991.
46. Zhao C, Annamalai L, Guo C., Kothandaraman N, Koh SC, et al. (2007) Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 9: 1-7.
47. Ye B, Cramer DW, Skates S.J., Gygi SP, Pratomo V, et al. (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9: 2904-2911.
48. Huang HL, Stasyk T, Morandell S., Dieplinger H, Falkensammer G, et al. (2006) Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 27: 1641-1650.
49. Yu B, Li SY, An P, Zhang Y.N., Liang ZJ, et al. (2004) Comparative study of proteome between primary cancer and hepatic metastatic tumor in colorectal cancer. World J Gastroenterol 10: 2652-2656.
50. Huang LJ, Chen SX, Huang Y, Luo W.J., Jiang HH, et al. (2006) Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 54: 87-94.
51. Mikuriya K, Kuramitsu Y, Ryozawa S., Fujimoto M, Mori S, et al. (2007) Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 30: 849-855.
52. Wang HY (2007) Laser capture microdissection in comparative proteomic analysis of hepatocellular carcinoma. Methods Cell Biol 82: 689-707.
53. Harn HJ, Chen YL, Lin P.C., Cheng YL, Lee SC, et al. (2010) Exploration of Potential Tumor Markers for Lung Adenocarcinomas by Two-Dimensional Gel Electrophoresis Coupled with Nano-LC/MS/MS. Journal of the Chinese Chemical Society 57: 180-188.
54. Kuppumbatti YS, Rexer B, Nakajo S., Nakaya K, Mira-y-Lopez R (2001) CRBP suppresses breast cancer cell survival and anchorage-independent growth. Oncogene 20: 7413-7419.
55. Farias EF, Marzan C, Mira-y-Lopez R (2005) Cellular retinol-binding protein-I inhibits PI3K/Akt signaling through a retinoic acid receptor-dependent mechanism that regulates p85-p110 heterodimerization. Oncogene 24: 1598-1606.
56. Kuppumbatti YS, Bleiweiss IJ, Mandeli J.P., Waxman S., Mira YLR (2000) Cellular retinol-binding protein expression and breast cancer. J Natl Cancer Inst 92: 475-480.
57. Reynolds CP, Matthay KK, Villablanca J.G., Maurer B.J. (2003) Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197: 185-192.
58. Lorkova L, Pospisilova J, Lacheta J., Leahomschi S, Zivny J, et al. (2012) Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. Oncol Rep 27: 318-324.
59. Kotnik P, Fischer-Posovszky P, Wabitsch M. (2011) RBP4: a controversial adipokine. Eur J Endocrinol 165: 703-711.
60. Forster DH, Daschner F.D. (1998) Acinetobacter species as nosocomial pathogens. Eur J Clin Microbiol Infect Dis 17: 73-77.
61. Velasco E, Byington R, Martins C.S., Schirmer M., Dias LC, et al. (2004) Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect 10: 542-549.
62. Pisani P, Parkin DM, Munoz N, Ferlay J. (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 6: 387-400.
63. de Martel C, Ferlay J, Franceschi S., Vignat J, Bray F, et al. (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13: 607-615.
64. Parsonnet J (1995) Bacterial infection as a cause of cancer. Environ Health Perspect 103 Suppl 8: 263-268.
65. Beebe JL, Koneman E.W. (1995) Recovery of uncommon bacteria from blood: association with neoplastic disease. Clin Microbiol Rev 8: 336-356.
66. Chang AH, Parsonnet J. (2010) Role of bacteria in oncogenesis. Clin Microbiol Rev 23: 837-857.
67. Mager DL (2006) Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med 4: 14.
68. Francois F, Roper J, Goodman A.J., Pei Z., Ghumman M, et al. (2008) The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 57: 16-24.
69. Ogbureke KU, Bingham C. (2012) Overview of Oral Cancer. In: Ogbureke KU, editor. Oral Cancer. Croatia: Intech. 3-20.
70. Hooper SJ, Wilson MJ, Crean S.J. (2009) Exploring the link between microorganisms and oral cancer: a systematic review of the literature. Head Neck 31: 1228-1239.
71. Bjorkholm B, Falk P, Engstrand L., Nyren O. (2003) Helicobacter pylori: resurrection of the cancer link. J Intern Med 253: 102-119.
72. Correa P, Houghton J. (2007) Carcinogenesis of Helicobacter pylori. Gastroen-terology 133: 659-672.
73. Peek RM Jr, Blaser M.J. (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2: 28-37.
74. Anttila TI, Lehtinen T, Leinonen M., Bloigu A, Koskela P, et al. (1998) Serological evidence of an association between chlamydial infections and malignant lymphomas. Br J Haematol 103: 150-156.
75. Kocazeybek B (2003) Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. J Med Microbiol 52: 721-726.
76. Sasaki M, Yamaura C, Ohara-Nemoto Y, Tajika S., Kodama Y, et al. (2005) Streptococcus anginosus infection in oral cancer and its infection route. Oral Dis 11: 151-156.
77. Tchoudakova A, Hensel F, Murillo A., Eng B, Foley M, et al. (2009) High level expression of functional human IgMs in human PER.C6 cells. MAbs 1: 163-171.
78. Zouali M (2002) Antibodies. eLS.
79. Brandlein S, Pohle T, Ruoff N., Wozniak E, Muller-Hermelink HK, et al. (2003) Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 63: 7995-8005.
80. Hanahan D, Weinberg R.A. (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
81. Cruz PM, Mo H, McConathy W.J., Sabnis N., Lacko A.G. (2013) The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol 4: 119.
82. Krupp M, Maass T, Marquardt J.U., Staib F., Bauer T, et al. (2011) The functional cancer map: a systems-level synopsis of genetic deregulation in cancer. BMC Med Genomics 4: 53.
83. Kolev M, Towner L, Donev R. (2011) Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz) 59: 407-419.
84. Rickles FR, Patierno S, Fernandez P.M. (2003) Tissue factor, thrombin, and cancer. Chest 124: 58S-68S.
85. Talens S, Leebeek FW, Demmers J.A., Rijken D.C. (2012) Identification of fibrin clot-bound plasma proteins. PLoS One 7: e41966.
86. Li D, Weng S, Yang B., Zander DS, Saldeen T, et al. (1999) Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 19: 378-383.
87. Michalik L, Wahli W. (2008) PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res 2008: 134059.
88. Yeng C, Osman E, Mohamed Z., Noordin R. (2010) Detection of immunogenic parasite and host-specific proteins in the sera of active and chronic individuals infected with Toxoplasma gondii. Electrophoresis 31: 3843-3849.